Adaptive Biotechnologies (ADPT) Competitors $5.82 +0.19 (+3.37%) (As of 11/8/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ADPT vs. FLDM, KOD, NVAX, GH, KYMR, APGE, TWST, CGON, SRRK, and SWTXShould you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include Fluidigm (FLDM), Kodiak Sciences (KOD), Novavax (NVAX), Guardant Health (GH), Kymera Therapeutics (KYMR), Apogee Therapeutics (APGE), Twist Bioscience (TWST), CG Oncology (CGON), Scholar Rock (SRRK), and SpringWorks Therapeutics (SWTX). These companies are all part of the "medical" sector. Adaptive Biotechnologies vs. Fluidigm Kodiak Sciences Novavax Guardant Health Kymera Therapeutics Apogee Therapeutics Twist Bioscience CG Oncology Scholar Rock SpringWorks Therapeutics Adaptive Biotechnologies (NASDAQ:ADPT) and Fluidigm (NASDAQ:FLDM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk. Which has stronger earnings and valuation, ADPT or FLDM? Fluidigm has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Fluidigm, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$170.28M5.04-$225.25M-$1.47-3.96Fluidigm$130.58M0.00-$59.24M-$0.78N/A Is ADPT or FLDM more profitable? Fluidigm has a net margin of -45.36% compared to Adaptive Biotechnologies' net margin of -126.49%. Fluidigm's return on equity of -40.15% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-126.49% -60.99% -27.99% Fluidigm -45.36%-40.15%-14.86% Does the MarketBeat Community favor ADPT or FLDM? Fluidigm received 423 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 63.94% of users gave Fluidigm an outperform vote while only 57.06% of users gave Adaptive Biotechnologies an outperform vote. CompanyUnderperformOutperformAdaptive BiotechnologiesOutperform Votes9357.06% Underperform Votes7042.94% FluidigmOutperform Votes51663.94% Underperform Votes29136.06% Does the media favor ADPT or FLDM? In the previous week, Adaptive Biotechnologies had 14 more articles in the media than Fluidigm. MarketBeat recorded 14 mentions for Adaptive Biotechnologies and 0 mentions for Fluidigm. Adaptive Biotechnologies' average media sentiment score of 0.53 beat Fluidigm's score of 0.28 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Overall Sentiment Adaptive Biotechnologies Positive Fluidigm Neutral Do analysts rate ADPT or FLDM? Adaptive Biotechnologies presently has a consensus target price of $6.25, suggesting a potential upside of 7.39%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Adaptive Biotechnologies is more favorable than Fluidigm.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Fluidigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in ADPT or FLDM? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 76.6% of Fluidigm shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 2.9% of Fluidigm shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, ADPT or FLDM? Adaptive Biotechnologies has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Fluidigm has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. SummaryAdaptive Biotechnologies beats Fluidigm on 10 of the 17 factors compared between the two stocks. Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADPT vs. The Competition Export to ExcelMetricAdaptive BiotechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$858.28M$3.23B$5.33B$8.94BDividend YieldN/A1.76%4.60%3.98%P/E Ratio-3.9625.55114.7816.30Price / Sales5.04322.031,278.8083.80Price / CashN/A148.8139.6634.37Price / Book2.735.235.895.85Net Income-$225.25M-$42.25M$118.17M$224.03M7 Day Performance9.60%15.89%4.79%4.94%1 Month Performance10.86%23.34%11.87%8.67%1 Year Performance29.05%54.61%40.63%30.16% Adaptive Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADPTAdaptive Biotechnologies3.0752 of 5 stars$5.82+3.4%$6.25+7.4%+16.8%$858.28M$170.28M-3.96709Earnings ReportNews CoverageGap UpFLDMFluidigmN/AN/AN/AN/A$283.76M$130.58M-4.76615Analyst ForecastKODKodiak Sciences3.6718 of 5 stars$3.90+1.6%N/A+141.7%$202.04MN/A-1.0490Upcoming EarningsPositive NewsNVAXNovavax3.7608 of 5 stars$9.12-2.5%N/A+29.5%$1.50B$983.71M-3.301,543Upcoming EarningsGHGuardant Health4.7178 of 5 stars$23.60+2.6%N/A+9.0%$2.83B$563.95M-5.771,779Analyst ForecastNews CoverageKYMRKymera Therapeutics1.2035 of 5 stars$47.07+1.3%N/A+204.8%$3.01B$78.59M-20.12170Analyst ForecastAPGEApogee Therapeutics2.0559 of 5 stars$56.30+3.3%N/A+240.3%$2.53BN/A-27.2091Upcoming EarningsTWSTTwist Bioscience2.7835 of 5 stars$42.05+1.2%N/A+149.6%$2.44B$245.11M-11.01990Insider SellingNews CoverageCGONCG Oncology3.0992 of 5 stars$36.78+2.4%N/AN/A$2.41B$200,000.000.0061Upcoming EarningsSRRKScholar Rock4.6183 of 5 stars$27.67-2.6%N/A+134.4%$2.27B$33.19M-12.46140Upcoming EarningsSWTXSpringWorks Therapeutics1.4812 of 5 stars$30.94+1.0%N/A+50.1%$2.27B$5.45M-6.98305Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Fluidigm Competitors Kodiak Sciences Competitors Novavax Competitors Guardant Health Competitors Kymera Therapeutics Competitors Apogee Therapeutics Competitors Twist Bioscience Competitors CG Oncology Competitors Scholar Rock Competitors SpringWorks Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADPT) was last updated on 11/8/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredI Got FiredStarting off with a few hundred bucks, it wasn't long before I started generating $1,000 a day. Then $10,00...Opportunistic Trader | SponsoredCan Trump Make Housing Great Again?Trump won. But can he undo the damage the Democrats have inflicted on this nation? Under Biden, inflatio...Behind the Markets | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
